Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (ORIGINAL) 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline.

2. (ORIGINAL) A pharmaceutical composition comprising 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline and a pharmaceutically acceptable carrier or diluent.

3. (ORIGINAL) A method of treating thrombocytopenia in a mammal in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound as described in claim 1.

4. (ORIGINAL) A method as claimed in claim 3, wherein the mammal is a human.

5. and 6. (CANCELED)

7. (ORIGINAL) The method of claim 3 wherein the compound is administered orally.

8. (ORIGINAL) The method of claim 3 wherein the compound is administered parenterally.

9. (CANCELED)

10. (ORIGINAL) A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound as described in claim 1, which process comprises bringing the compound described in claim 1 into association with the pharmaceutically acceptable carrier or diluent.

11. (ORIGINAL) The method of Claim 3 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine, interleukin or cytokine receptor agonist or antagonists, soluble receptors, receptor agonists or antagonist antibodies, or small molecules or peptides that act by the same mechanisms of one or more of said agents.

12. (ORIGINAL) The method of Claim 11 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SCF, FLT3 ligand, LIF, IL-3, IL-6, IL-1, Progenipoietin, NESP, SD-01, IL-8, or IL-5 or a biologically active derivative of any of said agents.

13. to 27. (CANCELED)

28. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to myelosuppression caused by chemotherapy or radiation therapy.

29. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to an organ transplant.

30. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to bone marrow, stem cell, or liver transplant.

31. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to idiopathic thrombocytopenia purpura (ITP).

32. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to myelodysplastic syndromes (MDS), aplastic anemia or leukemia.

33. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to viral, fungal, microbial or parasitic infection.

34. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to liver dysfunction.

35. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is due to surgical procedures.

36. (ORIGINAL) A method of claim 3 wherein said thrombocytopenia is drug – induced.

37. (ORIGINAL) A process for preparing the compound of claim 1, which process comprises:

i) dissolving 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one in an organic solvent or solvents, to form a solution;

ii) adding one or more equivalents of choline hydroxide to the solution; and

iii) isolating the prepared compound.

38. to 58. (CANCELED)

59. (ORIGINAL) The process of claim 37 wherein the solution contains a mixture of ethyl acetate and ethanol.

60. (ORIGINAL) The process of claim 37 wherein the solution contains tetrahydrofuran.